Market Fallers: G4S plc, GlaxoSmithKline plc, Glencore plc, Hammerson plc

Glencore plc
[shareaholic app="share_buttons" id_name="post_below_content"]

The trading price for G4S plc with ticker code: LON:GFS has moved down -1.73% or -4.2 points throughout today’s trading session so far. Market sellers were not positive during this period. The high for the period has peaked at 242.9 dropping as low as 237.7. Volume total for shares traded at this point reached 2,034,190 with the daily average traded share volume around 5,800,064. The 52 week high price for the shares is 342.6 about 99.5 points in difference on the previous days close and a 52 week low being 237.7 a difference of some 5.40 points. G4S plc now has a 20 moving average of 260.15 and a 50 day moving average of 270.7. The market capitalisation is now £3,706.76m at the time of this report. All share prices mentioned for this stock are traded in GBX. Mcap is measured in GBP. This article was written with the last trade for G4S plc being recorded at Thursday, March 22, 2018 at 1:56:57 PM GMT with the stock price trading at 238.9 GBX.

 

 

Shares in GlaxoSmithKline plc found using EPIC: LON:GSK has decreased -1.37% or -17.8 points during today’s session so far. Sellers have not remained optimistic throughout the session. The high for the period has reached 1288.4 and a low of 1275. The volume total for shares traded up to this point was 4,027,792 while the average shares exchanged is 8,537,821. The 52 week high price for the shares is 1724.5 amounting to 428.3 points difference from the previous days close and putting the 52 week low at 1235.2 which is a difference of 61 points. GlaxoSmithKline plc now has a 20 simple moving average of 1320.92 and now the 50 day moving average of 1328.74. The market cap now stands at £63,394.15m at the time of this report. The share price is in Great British pence. Mcap is measured in GBP. This article was written with the last trade for GlaxoSmithKline plc being recorded at Thursday, March 22, 2018 at 1:57:22 PM GMT with the stock price trading at 1278.4 GBX.

 

 

The trading price for Glencore plc with ticker code: LON:GLEN has decreased -3.39% or -12.6 points throughout the session so far. Sellers were far from a positive bunch throughout the session. The periods high has already touched 375.25 and hitting a low of 358.4. The total volume of shares exchanged through this period comes to 22,184,258 with the average number of shares traded daily being 48,126,404. The 52 week high for the share price is 416.91 amounting to 45.76 points different to the previous business close and a 52 week low sitting at 270 which is a variance of 101.15 points. Glencore now has a 20 SMA at 383.89 with a 50 day moving average now at 392.78. This puts the market capitalisation now at £51,200.13m at the time of this report. The share price is in GBX. Mcap is measured in GBP. This article was written with the last trade for Glencore being recorded at Thursday, March 22, 2018 at 1:57:17 PM GMT with the stock price trading at 358.55 GBX.

 

 

The share price for Hammerson plc ticker lookup code: LON:HMSO has stepped down -2.88% or -16.4 points in today’s trading session so far. Traders did not seem confident while the stock has been in play. The high for the period has peaked at 569.4 dropping as low as 546.8. The number of shares traded by this point in time totalled 4,893,482 with the daily average at 10,007,587. The 52 week high price for the shares is 52338 equating to 51768 points difference from the previous close and the 52 week low at 430.4 which is a difference of 139.6 points. Hammerson plc has a 20 SMA of 474.29 and now a 50 day moving average now of 483.8. The current market cap is £4,396.84m at the time of this report. All share prices mentioned for this stock are traded in GBX. Mcap is measured in GBP. This article was written with the last trade for Hammerson plc being recorded at Thursday, March 22, 2018 at 1:56:42 PM GMT with the stock price trading at 553.6 GBX.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
    GSK's Arexvy vaccine receives approval in Japan to protect adults aged 50-59 at increased risk from severe RSV infection, expanding its coverage.
    GSK Plc reports Q3 2024 results with strong growth in Specialty Medicines offsetting lower Vaccine sales. Core earnings rose by 5%, despite Zantac charges.
    GSK's new antibiotic gepotidacin earns FDA's Priority Review, marking potential first new uUTI oral treatment in 20 years, with decision due March 2025.

      Search

      Search